Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3Unknown 2Terminated 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 51Squamous Cell Carcinoma of Head and Neck 40Neoplasm Metastasis 30Neoplasms 27Breast Neoplasms 26Colorectal Neoplasms 23Carcinoma, Renal Cell 23Head and Neck Neoplasms 21Triple Negative Breast Neoplasms 20Carcinoma, Transitional Cell 20Stomach Neoplasms 19Ovarian Neoplasms 17Lung Neoplasms 15Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Carcinoma, Hepatocellular 12Urinary Bladder Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Multiple Myeloma 9Recurrence 8Endometrial Neoplasms 8Carcinoma, Merkel Cell 8Lymphoma, Non-Hodgkin 7Lymphoma 7Skin Neoplasms 6Mesothelioma 6Hodgkin Disease 6

Interventions

pembrolizumab 2Cisplatin 2Cetuximab 2zalutumumab 1poly ICLC 1enzalutamide 1abemaciclib 1Radiotherapy 1Papanicolaou Test 1Oxaliplatin 1Neoadjuvant Therapy 1Injections, Subcutaneous 1Human Papillomavirus DNA Tests 1High-Intensity Focused Ultrasound Ablation 1Gemcitabine 1Fluorouracil 1Everolimus 1Docetaxel 1Colposcopy 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Squamous Cell × pembrolizumab × Clear all
NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Seagen Inc.

Phase 1 Terminated
159 enrolled
DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT02837042 2022-06-21

Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

University of Alabama at Birmingham

Phase 2 Terminated
6 enrolled 10 charts
Genitourinary

Penile Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡